Triple antihypertensive therapy: Focus on efficacy and prognosis
Остроумова О. Д., Кочетков А. И., Стародубова А. В., Голобородова И. В., Смолярчук Е. А.
Рациональная фармакотерапия в кардиологии
Т. 14, Вып. 3, С. 458-468
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.20996/1819-6446-2018-14-3-458-468
Аннотация:
In the article, with regard to current clinical recommendations, the place of combined antihypertensive therapy, especially triple drugs regimens, is considered in the treatment of patients with arterial hypertension. Special focus is given to the body of evidence for the efficacy of valsartan and amlodipine, as the reference drug of angiotensin II receptor blockers and calcium channel blockers, respectively. Not only their high antihypertensive properties are demonstrated, but also a favorable effect on target-organ protection and prognosis is described. In particular, the possibilities of valsartan in reducing the severity of left ventricular hypertrophy and microalbuminuria are described, and its unique properties in the class of sartans that allow the use of this drug in patients with ischemic heart disease and chronic heart failure are emphasized. Data on the antiatherosclerotic effects of amlodipine and its proven ability to reduce cardiovascular risk are presented. Current data
Ключевые слова:
Amlodipine; Arterial hypertension; Fixed-dose combinations; Hydrochlorothiazide; Valsartan
amlodipine; hydrochlorothiazide; valsartan; antihypertensive therapy; Article; atherosclerosis; clinical practice; disease association; disease severity; drug efficacy; drug safety; heart left ventricle hypertrophy; human; hypertension; ischemic heart disease; microalbuminuria; practice guideline; prognosis; triple antihypertensive therapy
Язык текста: Русский
ISSN: 2225-3653
Остроумова О. Д. Ольга Дмитриевна 1968-
Кочетков А. И.
Стародубова А. В.
Голобородова И. В.
Смолярчук Е. А. Елена Анатольевна 1974-
Ostroumova O. D. Ol`ga Dmitrievna 1968-
Kochetkov A. I.
Starodubova A. V.
Goloborodova I. V.
Smolyarchuk E. A. Elena Anatolyevna 1974-
Triple antihypertensive therapy: Focus on efficacy and prognosis
Текст визуальный непосредственный
Рациональная фармакотерапия в кардиологии
Столичная издательская компания
Т. 14, Вып. 3 С. 458-468
2018
Статья
Amlodipine Arterial hypertension Fixed-dose combinations Hydrochlorothiazide Valsartan
amlodipine hydrochlorothiazide valsartan antihypertensive therapy Article atherosclerosis clinical practice disease association disease severity drug efficacy drug safety heart left ventricle hypertrophy human hypertension ischemic heart disease microalbuminuria practice guideline prognosis triple antihypertensive therapy
In the article, with regard to current clinical recommendations, the place of combined antihypertensive therapy, especially triple drugs regimens, is considered in the treatment of patients with arterial hypertension. Special focus is given to the body of evidence for the efficacy of valsartan and amlodipine, as the reference drug of angiotensin II receptor blockers and calcium channel blockers, respectively. Not only their high antihypertensive properties are demonstrated, but also a favorable effect on target-organ protection and prognosis is described. In particular, the possibilities of valsartan in reducing the severity of left ventricular hypertrophy and microalbuminuria are described, and its unique properties in the class of sartans that allow the use of this drug in patients with ischemic heart disease and chronic heart failure are emphasized. Data on the antiatherosclerotic effects of amlodipine and its proven ability to reduce cardiovascular risk are presented. Current data